Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
empowered allogeneic mesenchymal stem cells
- Development stage
- Preclinical
- Lead developer
- Beike Biotechnology
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intraarticular
01
Overview
Empowered allogeneic mesenchymal stem cells (MSCs) are a second-generation cell therapy candidate developed by Shenzhen Cell Bank, an entity associated with Beike Biotechnology. These cells are engineered or conditioned to possess enhanced therapeutic potency compared to conventional first-generation MSCs, specifically targeting the inflammatory and degenerative environment of knee osteoarthritis (KOA). The empowerment process is designed to improve cell survival, homing, and the secretion of bioactive paracrine factors that promote cartilage repair and suppress synovial inflammation. Currently in the preclinical stage, this therapy represents an advancement in allogeneic stem cell applications for degenerative joint diseases by aiming for higher standardization and efficacy.
- Other names
- 2nd-generation empowered mesenchymal stem cellsenhanced mesenchymal stem cellsempowered allogeneic MSCenhanced/empowered allogeneic MSCenhanced mesenchymal stem cell-Shenzhen Cell Bank-cell therapy-enhanced/empowered allogeneic MSC-knee osteoarthritis (KOA)
Beyond the preview
Go deeper on empowered allogeneic mesenchymal stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on empowered allogeneic mesenchymal stem cells.